of 46
8/3/2019 CXM Investor Presentation
1/46
October 25, 2011
Health Sciences& Regenerative
Medicine
InvestorPresentation
8/3/2019 CXM Investor Presentation
2/46
2
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Forward Looking Statements
This presentation may contain forward-looking statements, includingcomments concerning clinical trials and product development programs,evaluation of potential opportunities, the level of corporate expenditures,the assessment of Cardiums technology by potential corporate partners,capital market conditions, timing of events, cash consumption and other subjects. Actual results could differ materially from these forward-lookingstatements for many reasons, including the risks described under "RiskFactors" in the Companys Annual Report on Form 10-K and QuarterlyReports on Form 10-Q as filed with the Securities and ExchangeCommission. No guarantee about future results, performance or achievements can be made. Neither Cardium nor its agents intend toupdate any of the forward-looking statements after the date of thispresentation to conform them to actual results or to changes inexpectations.
8/3/2019 CXM Investor Presentation
3/46
3
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Capital-efficient business strategy focused on finding diamonds in the rough and leveraging
research and development investments by big pharma, venture and institutional investors Strategyintended to provide a diversified and more balanced portfolio of risk/return opportunities.
Excellagen Wound Care Management Platform: Initial product has now received FDA 510(k)clearance for U.S. marketing and sales Initial focus on diabetic foot ulcers Other product lineextensions currently under consideration Consistent with business strategy, support initial launch,seed the market, then monetize Now preparing for launch.
Generx Global Cardiovascular Platform: International cost-efficient Phase 3 / Registration Studynow cleared for initiation Study Design: 100 patients with SPECT imaging efficacy endpoint Initialmedical focus: Patients in Russia with advanced coronary artery disease who have limited access tocostly and rationalized bypass surgery and angioplasty / stent procedures (Russian CVD death rates5X greater than U.S.; average life expectancy for males 57 years) Preparing to initiate.
MedPodium In-House Brand Platform: Portfolio of premium, science-based, easy-to-use condition-specific nutraceuticals designed to promote personal health and well being for today's active,informed and professional lifestyles Seeking revenue-based strategic acquisitions in thenutraceutical space Preparing for initial retail launch of Nutra-Apps products in selectedgeographic areas.
Acquisition Search: Challenging economic environment continues to generate a steady stream ofdeal flow CXM remains highly selective focused primarily on late-stage clinical developmentopportunities and revenue-based businesses.
Key Investor Metrics: No outstanding debt, substantial trading liquidity, continuing news flowexpected Current capital structure provides for significant economic upside potential as CXMexecutes business strategy Capital-efficient ATM Shelf Registration in place.
Investment Highlights
8/3/2019 CXM Investor Presentation
4/46
4
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Company Acquisition CurrentKey Product
Portfolio ofCardiovascular Growth
Factor Biologicsfrom Schering AG
Generx [Ad5FGF-4]
Phase 3
Registration Study forInternational Markets
Endovascular
TherapeuticHypothermia System
Strategic
Sale to
DNA-ActivatedMatrices for Wound& Orthopedic Repair
Excellagen Wound CareFDA 510(k)Clearance
Preparing for InitialMarket Launch
Portfolio Status
CollateralTherapeutics
InnerCoolTherapies
Tissue RepairCompany
8/3/2019 CXM Investor Presentation
5/46
5
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen
8/3/2019 CXM Investor Presentation
6/46
6
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen: Medical Focus
ChronicDiabetic
Foot Ulcers
OtherWounds:IncludingSurgical& Burns
Pressure
Ulcers
Venous
Ulcers
FormulatedCollagen
8/3/2019 CXM Investor Presentation
7/46
7
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Wound Care Management PlatformFormulated Collagen Topical Gel
Highly-Refined Fibrillar Type I Bovine Collagen
Specialized Formulation
Kit Provides for up to Four Applications over 12 WeeksImmediately Following SurgicalDebridement Procedure
Pre-Formulated Ready-to-Use.One 0.5 cc Excellagen Syringe willTreat Wounds up to 5cm 2 in Size
Pre-Filled Single Use Sterile Syringes
Refrigerated Storage
For Professional Use Only
8/3/2019 CXM Investor Presentation
8/46
8
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen: Initial Medical Focus
Wound Care Management for Diabetic Foot Ulcers
8/3/2019 CXM Investor Presentation
9/46
9
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen Treatment:Diabetic Foot Ulcers
Debride Treat Bandage Offload1 2 3 4
www.excellagen.com
8/3/2019 CXM Investor Presentation
10/46
10
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen: Competitive Landscape
HomeTreatmentby Patient:
Regranex Topical Gel &OTC Products
MedicalDevices:
NegativePressure Wound
Therapy
Dermal / TissueEngraftment:
ProfessionalUse Standard of
Care Enhancement:Excellagen
Intregra Flowable Oasis
Dermagraft
Apligraf Graftjacket
8/3/2019 CXM Investor Presentation
11/46
11
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen: Strategic Fit with CurrentAdvanced Wound Healing Products
Advanced Wound Care
Treatments for Diabetic Foot Ulcers
Tissue Regeneration
Advanced Wound Healing
Professional Use
Dermal EngraftmentSpecific Therapeutic UseClaims for DFUs OnlyPrep: 24 Step Process(Requiring Documentation)Storage: Frozen (-75 C)
Higher Cost
Professional Use
Adjunct to Standard of CareSurgical DebridementBroad Product Use
ApplicationsPrep: Ready UseStorage:
Refrigeration (2
- 8
C)Lower Cost
Dermagraft is a Registered Trademark of Advanced BioHealing, a subsidiary of Shire PLC.
8/3/2019 CXM Investor Presentation
12/46
12
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen: Potential for Diabetic Foot Ulcer Market
Diabetic Foot Ulcers AnnualU.S. Patients with Diabetic Foot Ulcers 1
Average Number of PhysicianVisits per Year 2
Projected Patient Visits InvolvingSurgical Debridement (est. 50%)
1.3 Million
14 per patient
7 per patient
Potential Number of U.S. SurgicalDebridement Procedures for DFUs 9.1 Million
Potential Revenue Opportunity at VaryingExcellagen Market Penetration Levels 3
0.5%1.0%2.0%4.0%6.0%
8.0%10.0%
$5 Million$10 Million$20 Million$35 Million$50 Million
$70 Million$80 Million
1 American Diabetes Association.2 U.S. Department of Health and Human Services: Agency for Healthcare Research and Quality.
3 Assumes $95.00 per Excellagen Treatment.
8/3/2019 CXM Investor Presentation
13/46
13
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MATRIX Clinical Study DataThe Science of Formulated Collagen Gel
Blume P, et al. Wound Repair Regen . 2011 May-Jun;19(3):302-8.
PeerReviewedMedicalJournalArticle
Formulated collagen gel causes a large and rapid time-dependent effect on tissue growth rates. A single application increases the healing rate of neuropathic DFUs..., and more frequent applications hold promise to significantly improve overall incidence of complete wound closure.
8/3/2019 CXM Investor Presentation
14/46
14
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
In Vitro Research Study DataThe Science of Formulated Collagen Topical Gel
Activated Platelet Release of PDGF
8/3/2019 CXM Investor Presentation
15/46
15
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Diabetic Foot Ulcers: Continuing Unmet Medical Need
Looking for a New Wound Care Pathway
Diabetic patients with non-healing footulcers are frustrated and disappointed withtreatment outcomes. Even with access toquality medical care and advanced woundtreatment modalities, patients in Cardiums
Matrix clinical study had unhealed footulcers averaging 69 weeks (1.3 years).
8/3/2019 CXM Investor Presentation
16/46
16
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen: Web-Based Banner Ad
8/3/2019 CXM Investor Presentation
17/46
17
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Excellagen: Web-BasedDirect-to-Consumer Positioning
Non-healing foot ulcers are serious.If you have received treatment withoutsuccess, become part of the solution,try something new! Find a new woundcare pathway with Excellagen
Find a New Wound Care Pathway
8/3/2019 CXM Investor Presentation
18/46
18
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Generx Late-Stage Clinical Development
8/3/2019 CXM Investor Presentation
19/46
8/3/2019 CXM Investor Presentation
20/46
20
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Cardiovascular Angiogenesis
8/3/2019 CXM Investor Presentation
21/46
21
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Generx Potential Economic Opportunity
Unit VolumeOpportunity per
Economic Region
Target Revenue per Dose
Level I
$2,000 / dose
Level II
$3,000 / dose
Level III
$4,000 / dose
50,000 doses $100 Million $150 Million $200 Million
100,000 doses $200 Million $300 Million $400 Million
150,000 doses $300 Million $450 Million $600 Million
200,000 doses $400 Million $600 Million $800 Million
8/3/2019 CXM Investor Presentation
22/46
22
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Generx : Historical Perspective
CollateralTherapeutics
(NASDAQ)
University of CaliforniaSan Diego
1996
Discovery, Licensingand Initial
Preclinical Studies
1997 - 2005 2005 - Present Current Status
Schering AG
Phase 1/2 toPhase 2b/3
As Strategic Partner with CollateralTherapeutics
CardiumTherapeutics
Formed toAcquire
Technology fromSchering / Bayer
FDA Phase 3 Clearancewith Fast Track Status& Phase 3 Clearancefor Registration Study
in Russia
CommercialInternationalDevelopment
Activities
RussiaBrazilIndia
Schering AcquiresCollateral in 2002
for $160 Million
8/3/2019 CXM Investor Presentation
23/46
23 2011 Cardium Therapeutics, Inc.
GENERX [Ad5FGF-4]
Generx [Ad5FGF-4] represents a new regenerativemedicine therapeutic class of DNA-based biologics that
is being developed for interventional cardiology that isdesigned to promote a disease-modifying physiologicalresponse which stimulates the growth of microvascular circulation based on the one-time administration, using astandard cardiac catheter, as a treatment for patientswith advanced coronary artery disease.
Generx is currently being developed for internationalmarkets outside the United States as a treatmentalternative for patients who may not have access tocostly and invasive advanced care revascularizationprocedures, including coronary artery bypass surgeryand angioplasty/stents, or may not be optimalcandidates for these procedures.
8/3/2019 CXM Investor Presentation
24/46
24
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Non-surgical delivery by intracoronary administration byinterventional cardiologist during an angiogram procedure
Utilizes standard balloon catheter which can be easily
integrated into diagnostic angiogram procedures or with other percutaneous coronary interventions
New induced transient ischemia / reperfusion techniques aredesigned to enhance DNA uptake and expression in the heart
40% administered to right coronary circulation and60% to left coronary circulation
Generx [Ad5FGF-4]Proprietary Intracoronary Administration of
DNA-Based Cardiovascular Growth Factor Therapeutic
8/3/2019 CXM Investor Presentation
25/46
8/3/2019 CXM Investor Presentation
26/46
26
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
DNA-Based Delivery
Angiogenic ResponseGenerx [Ad5FGF-4](alferminogene tadenovec)
Generx has been evaluated in studies of over 650 patients (including 450Generx-treated patients) in four multi-center, double-blind, placebo-controlledclinical studies at 100 medical centers. Generx is the most clinically advancedDNA-based cardiovascular angiogenic growth factor therapeutic in the world.
AGENT-2 - Representative Generx-treated patient: 77%improvement in cardiac perfusion at 8 weeks equivalentto bypass surgery and PCI (angioplasty/stenting) at one year.
One-Time Treatment
The Therapeutic Process ofCardiac Microvascular Angiogenesis
SPECT Imaging
8/3/2019 CXM Investor Presentation
27/46
27
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
AGENT 2: Primary Endpoint SPECT Imaging AngiogenicMechanism of Action Study
p=0.14
p
8/3/2019 CXM Investor Presentation
28/46
8/3/2019 CXM Investor Presentation
29/46
8/3/2019 CXM Investor Presentation
30/46
30
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Developing new andinnovative, cost-effective
advanced care for coronaryheart disease patients ininternational markets
Generx Cardio Chant
8/3/2019 CXM Investor Presentation
31/46
31 2011 Cardium Therapeutics, Inc.
Generx [Ad5FGF-4]Product Focus for Russian Federation
Generx is being developed to promote the growth of microvascular circulation in the heart. It is administered by a cardiologist through a cardiac catheter during an outpatient procedure.
The product is a new treatment option for patients with myocardial ischemia due to advanced coronary artery disease that have limited access to advanced medical care including coronary angioplasty and stents as well as coronary artery by-pass surgery or patients who are
not optimal candidates for those procedures.A long-term study (n = 845) has shown that patients with a higher collateral blood flow index may have an improved mortality benefit when compared to patients with a relatively lower collateral blood flow index.
Selected Health Statistics Benchmarks
Demographic Metrics UnitedStatesRussian
Federation Variance
Average Life Expectancy - Males 75 57 1 - 24%
Cardiovascular Death Rates per 100,000 (Ages 35-74) Males 2 283 1,555 5.5X
Cardiovascular Death Rates per 100,000 (Ages 35-74) Females 2 145 659 4.5X
1R I A Novosti, Feb. 2, 2010.2 American Heart Association 2009.
CONFIDENTIAL
8/3/2019 CXM Investor Presentation
32/46
32
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Why Generx for India?64.0 Million Indians are Projected to have
Coronary Artery Disease by 2015
Generx [Ad5FGF-4]Coronary Anatomy andCardiovascular Disease
Issues in India 1
Simpler administration and cost effective treatmentcompared to bypass and stents
First non-surgical revascularization therapy
Stimulates the growth of microvascular circulationin patients with coronary artery disease
Women and patients with more advanceddisease demonstrated significant treatmenteffect based on distal disease
New induced transient ischemiatechniques may reduce treatmentvariability in earlier stage patients
Involvement at younger age
Smaller coronary arteries
Diffuse distal disease
Multi-vessel disease
Higher incidence in women
1Source: Cardiovascular Disease Trends in India Naresh Terhan, Escorts Heart Institute and Research Centre
8/3/2019 CXM Investor Presentation
33/46
8/3/2019 CXM Investor Presentation
34/46
34
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c
.
We found a significant, gender- specific beneficial effect of
Ad5FGF-4 on total ETT time, time to
1 mm ST-segment depression, time to angina and CCS Class in women.This is the first clinical report of a gender difference in response to
cardiac angiogenic therapy.
JACCSeptember 11, 2007
The potential importance of the observed gender-specific
angiogenic response on the clinical treatment of refractory
angina is substantial and
deserves further investigation.
Generx AGENT 3 & 4
Summary Research
8/3/2019 CXM Investor Presentation
35/46
35
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
A well-functioning coronary collateral circulation saves lives in
patients with chronic stable coronary artery disease.
Beneficial Effects of aDisease-Induced
Angiogenic VascularizationSummary Research
From Meier et al . Circulation 2007; 116:975-83.
8/3/2019 CXM Investor Presentation
36/46
36
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Coronary Artery DiseaseNatural Disease-Induced Angiogenic Vascularization
ONOFF
8/3/2019 CXM Investor Presentation
37/46
37
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium Initial ProductsWeb-Based Boutique
MedPodium is a portfolio of premium, science-based, easy-to-use condition-specific nutraceuticals, metabolics,aesthetics, and other products designed to promote personal health and well being based on natural formulationsfor today's active, informed and professional lifestyles. MedPodium's products address healthy lifestyle intereststhat are increasingly important in our technology-based society, including millennials (young adults aged 20 to 35)who are leading the information revolution. The MedPodiums products will feature sealed capsules, quality, easyto use pills, and will also include, fast-acting drops and sprays, and transdermal delivery system.
www.medpodium.com
8/3/2019 CXM Investor Presentation
38/46
38
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium: Product Strategy
NutraceuticalFormulation
PharmaceuticalPhilosophy
X
MillennialTarget Market
8/3/2019 CXM Investor Presentation
39/46
39
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium: Product Differentiation
8/3/2019 CXM Investor Presentation
40/46
40
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium: Conceptual Product Focus
PositiveBrain
ChemistryModulators
MillennialTargetMarket
(Age 20 35)
Nutra Apps
8/3/2019 CXM Investor Presentation
41/46
41
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
Level I Level II
Sugar
Caffeine
iPod
Nutraceuticals
Nicotine
Alcohol
Medicinal Marijuana
ADHD (Ritalin )
Anxiety ( Xanax )
Depression ( Prozac, Zoloft )
Sleep ( Lunesta )
Relax ( Valium )
Pain ( Vicoden, Oxycontin )
MedPodium: Millennial Brain Chemistry Modulators
8/3/2019 CXM Investor Presentation
42/46
42
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium Nutra-AppsConvenience & Retail Stores
8/3/2019 CXM Investor Presentation
43/46
43
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium: Nutra AppsCommercial C-Store Positioning
Conceptual Product Inspiration
8/3/2019 CXM Investor Presentation
44/46
44
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium: Nutra AppsCommercial C-Store Promotion
8/3/2019 CXM Investor Presentation
45/46
45
2 0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .
MedPodium: Nutra AppsCommercial Strategy
Stage I
2011 2013
InitialConvenience
StoreDistribution
Program
Stage II
Broader,Product
Distribution toFood, Drug
& Mass Market
8/3/2019 CXM Investor Presentation
46/46
0 1 1 C a r d
i u m
T h e r a p e u
t i c s ,
I n c .